152 related articles for article (PubMed ID: 17107350)
1. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.
Lasho TL; Pardanani A; McClure RF; Mesa RA; Levine RL; Gilliland DG; Tefferi A
Br J Haematol; 2006 Dec; 135(5):683-7. PubMed ID: 17107350
[TBL] [Abstract][Full Text] [Related]
2. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Pardanani AD; Levine RL; Lasho T; Pikman Y; Mesa RA; Wadleigh M; Steensma DP; Elliott MA; Wolanskyj AP; Hogan WJ; McClure RF; Litzow MR; Gilliland DG; Tefferi A
Blood; 2006 Nov; 108(10):3472-6. PubMed ID: 16868251
[TBL] [Abstract][Full Text] [Related]
3. Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.
Pardanani A; Lasho TL; Finke C; Mesa RA; Hogan WJ; Ketterling RP; Gilliland DG; Tefferi A
Stem Cells; 2007 Sep; 25(9):2358-62. PubMed ID: 17540852
[TBL] [Abstract][Full Text] [Related]
4. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
5. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
[TBL] [Abstract][Full Text] [Related]
6. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
7. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival.
Tefferi A; Lasho TL; Huang J; Finke C; Mesa RA; Li CY; Wu W; Hanson CA; Pardanani A
Leukemia; 2008 Apr; 22(4):756-61. PubMed ID: 18216871
[TBL] [Abstract][Full Text] [Related]
8. Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation.
Hussein K; Theophile K; Buhr T; Beller A; Kreipe H; Bock O
Br J Haematol; 2009 Jun; 145(5):673-5. PubMed ID: 19344408
[No Abstract] [Full Text] [Related]
9. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
[TBL] [Abstract][Full Text] [Related]
10. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
11. Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.
Daly S; Conneally E; Langabeer SE
Acta Haematol; 2009; 121(4):221-2. PubMed ID: 19521067
[No Abstract] [Full Text] [Related]
12. MPLW515L mutation in acute megakaryoblastic leukaemia.
Hussein K; Bock O; Theophile K; Schulz-Bischof K; Porwit A; Schlue J; Jonigk D; Kreipe H
Leukemia; 2009 May; 23(5):852-5. PubMed ID: 19194467
[TBL] [Abstract][Full Text] [Related]
13. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
[TBL] [Abstract][Full Text] [Related]
14. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
Pardanani A; Guglielmelli P; Lasho TL; Pancrazzi A; Finke CM; Vannucchi AM; Tefferi A
Leukemia; 2011 Dec; 25(12):1834-9. PubMed ID: 21691276
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
[TBL] [Abstract][Full Text] [Related]
16. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT.
Alchalby H; Badbaran A; Bock O; Fehse B; Bacher U; Zander AR; Kröger N
Bone Marrow Transplant; 2010 Sep; 45(9):1404-7. PubMed ID: 20062088
[TBL] [Abstract][Full Text] [Related]
17. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
[TBL] [Abstract][Full Text] [Related]
18. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.
Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H
Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228
[TBL] [Abstract][Full Text] [Related]
19. Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults.
DeLario MR; Sheehan AM; Ataya R; Bertuch AA; Vega C; Webb CR; Lopez-Terrada D; Venkateswaran L
Am J Hematol; 2012 May; 87(5):461-4. PubMed ID: 22389089
[TBL] [Abstract][Full Text] [Related]
20. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.
Kittur J; Knudson RA; Lasho TL; Finke CM; Gangat N; Wolanskyj AP; Li CY; Wu W; Ketterling RP; Pardanani A; Tefferi A
Cancer; 2007 Jun; 109(11):2279-84. PubMed ID: 17440984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
